3D-bioprinted model mimics real human heart properties
Researchers from Israel have created a 3D-printed model that captures the immunological,...Read more on AuntMinnie.comRelated Reading: 3D printing reduces liver transplant costs, surgery time 3D printing helps separate rare case of conjoined twins 3D printing technique improves heart valve sizing 3D-printed aortas could work well for TAVR Flexible 3D-printed heart replicates size, texture (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 16, 2019 Category: Radiology Source Type: news

TAVR Puts the Swagger Back in Mick Jagger
Rolling Stones frontman Mick Jagger’s recent surgery is putting a huge spotlight on the transcatheter aortic valve replacement (TAVR) market. Late last week, Jagger tweeted that his procedure was a success and thanked fans for their support.   Thank you everyone for all your messages of support, I’m feeling much better now and on the mend - and also a huge thank you to all the hospital staff for doing a superb job. — Mick Jagger (@MickJagger) April 5, 2019 Problems for the 75-year-old began late last month after the rocker fell ill. As a result, the Rolling...
Source: MDDI - April 10, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

GE Healthcare in AI Collaboration with ACR
Larger medtech companies are really starting to see the value of artificial intelligence. Some companies like GE Healthcare have already taken a deep-dive into the world of AI. The Chicago-based company just announced achieving another significant milestone into AI by farming a partnership with American College of Radiology (ACR). The collaboration will have GE Healthcare integrating the Edison platform with the ACR AI-Lab. Edison serves as a “digital thread” for GE Healthcare’s existing AI partnerships and products, the partnership will extend these services and allow ...
Source: MDDI - April 9, 2019 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Business Source Type: news

Mick Jagger is giving TAVR a boost: Here ’ s how
Mick Jagger during a concert in Warsaw, Poland in 2018 [Image by Jerzy Bednarski – Own work, CC BY-SA 4.0]A successful transcatheter aortic valve replacement (TAVR) recovery for rock icon Mick Jagger could be good news for companies such as Medtronic (NYSE:MDT) and Edwards Lifesciences (NYSE:EW) that make devices for the procedure, according to analysts following the medical device industry. The Rolling Stone frontman tweeted Friday that he was feeling better and on the mend after undergoing the procedure at a New York hospital. “We think Mick Jagger’s TAVR procedure will likely raise awareness of aortic ...
Source: Mass Device - April 8, 2019 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News Cardiovascular Featured News Well Edwards Lifesciences Medtronic tavr Source Type: news

Did Mick Jagger Get A New Aortic Valve? What You Need To Know
The lead singer for the Rolling Stones reportedly just underwent a successful transcatheter aortic valve replacement (TAVR). (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 6, 2019 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

Mick Jagger'On The Mend' After Reportedly Getting A New Aortic Valve
The lead singer for the Rolling Stones reportedly just underwent a successful transcatheter aortic valve replacement (TAVR). (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 6, 2019 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

Mick Jagger Recovering After Heart Surgery
Jagger had a procedure called transcatheter aortic valve replacement. Doctors accessed his heart valve using a catheter that was inserted through his femoral artery, avoiding the need to open Jagger's chest. (Source: WebMD Health)
Source: WebMD Health - April 5, 2019 Category: Consumer Health News Source Type: news

Edwards Lifesciences doubles down on Irish plant
Edwards Lifesciences (NYSE:EW)  reportedly plans to double its investment in a plant it’s building in Ireland that’s expected to add 600 jobs to the local economy. Last year the Irvine, Calif.-based company said it planned to build a new, 170,000-square-foot facility in Limerick to manufacture delivery components for its transcatheter heart valves. At the time the project was slated to cost about $93.3 million (EU €80 million) and open in 2021. Today Edwards said it will add another $93.3 million to the tab as it plans to build a larger plant but held to the 2021 timetable as it broke ground on t...
Source: Mass Device - April 5, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Business/Financial News Replacement Heart Valves Edwards Lifesciences Source Type: news

Tioga Medical raises $15m to support transcath mitral, tricuspid valve tech
Newly formed Shifamed portfolio company Tioga Medical said today that it closed a $15 million Series A preferred stock financing round to support its transcatheter mitral and tricuspid valve replacement technology. The Campbell, Calif.-based company said that it is developing novel transcatheter valve replacement technology intended to be simpler and less invasive than current mitral and tricuspid valve replacement approaches. Tioga Medical will initially focus on technology for mitral valve replacement, stating that there is a “significant clinical need for less invasive, transcatheter approaches for mitral val...
Source: Mass Device - April 4, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiac Implants Cardiovascular Catheters Replacement Heart Valves tiogamedical Source Type: news

AHA News: Surgery Like Jagger: Doctors Explain Heart Valve Problems, Treatment
WEDNESDAY, April 3, 2019 (American Heart Association News) -- Rolling Stones fans were concerned by the news Mick Jagger needs a new heart valve. But they'll be happy to know that these days most patients in his situation can get what they need --... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 4, 2019 Category: General Medicine Source Type: news

AHA News: Surgery Like Jagger: Doctors Explain Heart Valve Problems, Treatment
Title: AHA News: Surgery Like Jagger: Doctors Explain Heart Valve Problems, TreatmentCategory: Health NewsCreated: 4/4/2019 12:00:00 AMLast Editorial Review: 4/4/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - April 4, 2019 Category: Cardiology Source Type: news

For TAVR, Inverse Link Identified for Hospital Volume, Mortality
WEDNESDAY, April 3, 2019 -- Hospital volume is inversely associated with mortality for transfemoral transcatheter aortic-valve replacement (TAVR) procedures, according to a study published online April 3 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 3, 2019 Category: Pharmaceuticals Source Type: news

Mick Jagger to Have Heart Valve Surgery
Title: Mick Jagger to Have Heart Valve SurgeryCategory: Health NewsCreated: 4/2/2019 12:00:00 AMLast Editorial Review: 4/3/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - April 3, 2019 Category: Cardiology Source Type: news

Explained: The operation Mick Jagger will likely undergo to fix damaged valve
The 75-year-old singer announced his scheduled operation on Monday, two weeks after a major study found the relatively new tube method is safer than open-heart surgery. (Source: the Mail online | Health)
Source: the Mail online | Health - April 3, 2019 Category: Consumer Health News Source Type: news

Mick Jagger Facing Heart Surgery
Heart-valve replacement surgery typically comes with a recover of anywhere from a week to 4-to-6 weeks for open-heart surgery. (Source: WebMD Health)
Source: WebMD Health - April 2, 2019 Category: Consumer Health News Source Type: news

Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC
Review'real-world'clinical use of three methods of transcatheter mitral valve replacement.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 1, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

CMS touts ‘ more flexibility ’ in new TAVR coverage requirements
The Centers for Medicare and Medicaid Services have proposed new policy that could expand the use of transcatheter aortic valve replacement procedures, touting that it may provide more flexibility for starting and maintaining TAVR programs. The original National Coverage Determination for TAVR procedures was cleared in 2012, when the technology and associated procedure was still new. The new policy from CMS looks to update requirements based on new information about the safety and viability of the procedures. The new proposal, released yesterday, would reduce the number of cardiac surgeons required to independently examine...
Source: Mass Device - March 27, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiac Implants Cardiovascular Replacement Heart Valves Centers for Medicare and Medicaid Services (CMS) Source Type: news

Top presentations at #AGS19 address prescription patterns, hypertension, frailty
(American Geriatrics Society) Data on the chronic use of opioids following spinal surgery, intensified treatment of high blood pressure after hospital discharge, and assessments of which frailty measures best predict poor outcomes following aortic heart valve replacement are among headline presentations at the American Geriatrics Society (AGS) 2019 Annual Scientific Meeting (#AGS19), held May 2-4 in Portland, Ore. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 27, 2019 Category: International Medicine & Public Health Source Type: news

What Will a'Historic Day' for TAVR Mean in Clinical Practice? What Will a'Historic Day' for TAVR Mean in Clinical Practice?
Raj Makkar, MD, discusses the PARTNER-3 and Evolut trials of transcatheter aortic valve replacement in low-surgical-risk patients and his registry data on TAVR for bicuspid aortic stenosis at ACC.19.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Aortic Stenosis: Watchful Waiting Works Only for So Long
(MedPage Today) -- Study supports timely aortic valve replacement in asymptomatic patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 23, 2019 Category: Cardiology Source Type: news

She Owed $227,000 in Medical Bills —Even With Insurance. Here’s What it Took to Pay Them
The first surprise was the massive heart attack, which struck as Debbie Moehnke waited in a Vancouver, Wash., medical clinic last summer. “She had an appointment because her feet were swollen real bad,” said Larry Moehnke, her husband. “But she got in there and it was like, ‘I can’t breathe, I can’t breathe!’” Her life suddenly at risk, the 59-year-old was rushed by ambulance, first to a local hospital, where she was stabilized, and then, the next day, to Oregon Health & Science University across the river in Portland for urgent cardiac care. That meant heart bypass surge...
Source: TIME: Health - March 21, 2019 Category: Consumer Health News Authors: JoNel Aleccia / Kaiser Health News Tags: Uncategorized medicine Source Type: news

Neovasc claims win in German TMVR patent case against Edwards unit CardiAQ Valve
Neovasc (NSDQ:NVCN) today claimed a win in its patent infringement war with Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve Technologies, saying a German appeals court dismissed a case there. In June 2017 the District Court in Munich ruled that CardiAQ Valve contributed to the creation of Neovasc’s Tiara transcatheter mitral valve replacement, awarding”co-entitlement” rights to the patent in Europe. Both sides appealed that ruling, in the course of which CardiAQ withdrew its total ownership claim but asserted partial ownership, Vancouver-based Neovasc said today. Munich’s Higher Re...
Source: Mass Device - March 21, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Featured Legal News Replacement Heart Valves Wall Street Beat CardiAQ Valve Technologies Edwards Lifesciences neovasc Source Type: news

Echocardiography identifies patients for valve repair
Echocardiography can help determine which patients with heart failure and leaking...Read more on AuntMinnie.comRelated Reading: Lung ultrasound beats chest x-ray for heart failure detection Societies renew call to pull ultrasound contrast warning ACC, ASE release echocardiography training guidance ASE offers TEE guidelines for congenital heart disease Heart valve-tracking algorithm boosts viability of 4D MRI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 19, 2019 Category: Radiology Source Type: news

ACC 2019 Roundup: Abiomed Impella RP post-market study shows benefit in select patient group
Abiomed (NSDQ:ABMD) today released 18-month post-approval study data from patients treated with its Impella RP, touting a benefit to survival for specifically selected “Recover Right” protocol patients. Results from the study were presented at the American College of Cardiology’s 68th Annual Scientific Sessions in New Orleans, the Danvers, Mass.-based company said. The review follows a release posted by the FDA last month warning of a 17.4% survival rate with the Impella RP heart pump system, approximately 55% lower than the rate noted in the premarket study of the device. Abiomed said that it met wi...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Featured Patient Monitoring Replacement Heart Valves Abbott Abiomed Medtronic Source Type: news

ACC 2019: Medtronic, Edwards low-risk TAVR trial data could pave way to new indications
Results from trials of both Medtronic‘s (NYSE:MDT) and Edwards Lifesciences‘ (NYSE:EW) transcatheter aortic valve replacement systems exploring their use in low-risk patients indicated that the devices were as safe as open surgery, paving the way for possible new indications for TAVR technology. Data from the trials were presented over the weekend at the American College of Cardiology 68th Annual Scientific Session 2019 in New Orleans and simultaneously published in the New England Journal of Medicine. Currently, TAVR devices are only approved by the FDA for treating severe aortic valve stenosis in patients at ...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Replacement Heart Valves Edwards Lifesciences Medtronic Source Type: news

Boom TAVR Low-Risk Trials Usher in a New Era in Cardiology Boom TAVR Low-Risk Trials Usher in a New Era in Cardiology
The results are impressive for transcatheter aortic valve replacement in low-surgical-risk patients, but longer-term data on durability will be crucial, notes John Mandrola, MD.theheart.org on Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 18, 2019 Category: Surgery Tags: Cardiology Expert Column Source Type: news

Boom: TAVR Low-Risk Trials Usher in a New Era in Cardiology Boom: TAVR Low-Risk Trials Usher in a New Era in Cardiology
The results are impressive for transcatheter aortic valve replacement in low-surgical-risk patients, but longer-term data on durability will be crucial, notes John Mandrola, MD.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 18, 2019 Category: Cardiology Tags: Cardiology Expert Column Source Type: news

TAVR Low-Risk Studies Get Standing Ovation at ACC TAVR Low-Risk Studies Get Standing Ovation at ACC
The success of the two trials of transcatheter aortic valve replacement in low-surgical-risk patients stole the show at the ACC today.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 18, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Tens of Thousands of Heart Patients May Not Need Open-Heart Surgery
Replacement of the aortic valve with a minimally invasive procedure called TAVR proved effective in younger, healthier patients. (Source: NYT Health)
Source: NYT Health - March 16, 2019 Category: Consumer Health News Authors: GINA KOLATA Tags: Medical Devices Surgery and Surgeons Heart Aorta Catheters Clinical Trials American College of Cardiology Columbia University Edwards Lifesciences Corporation Medtronic Inc New England Journal of Medicine Source Type: news

PARTNER 3: TAVR Success in Low-Risk Patients PARTNER 3: TAVR Success in Low-Risk Patients
The procedure using the SAPIEN 3 valve showed a significantly lower rate of death, stroke, and rehospitalization at 1 year vs surgery in patients with severe aortic stenosis at low surgical risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 16, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies
Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - March 16, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Edwards, Medtronic heart valve systems prove worth in low-risk patients: studies
Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results presented on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - March 16, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

In study, TAVR is superior to surgery for low-risk patients with aortic valve stenosis
(Columbia University Irving Medical Center) A large clinical trial has found that a minimally invasive procedure to replace a narrowed heart valve performed better than surgery in patients who were good candidates for surgery. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 16, 2019 Category: International Medicine & Public Health Source Type: news

FDA ramps up scrutiny of materials in medical devices
(Image by Michael Longmire on Unsplash) The FDA said today it has begun more closely scrutinizing the roles of certain materials associated with harm to patients who have breast implants, nitinol-containing devices, metal-on-metal hip implants and devices made from animal-derived substances. It’s the latest in a series of statements the agency has issued following increasingly harsh public criticism of its efforts to regulate the medical device industry. In the past year, Netflix’s documentary “The Bleeding Edge” and the International Consortium of Investigative Journalists’ &ld...
Source: Mass Device - March 15, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: 510(k) Blog Cardiovascular Featured Food & Drug Administration (FDA) Implants Materials Testing Metal-on-Metal News Well Oncology Orthopedics Regulatory/Compliance Replacement Heart Valves Stents Surgical Women's Health ani Source Type: news

Abbott Wins Additional Indication for MitraClip
Abbott Laboratories has received an expanded indication for MitraClip. The Abbott Park, IL-based company’s new indication addresses the secondary form of mitral regurgitation and significantly increases the amount of people with MR able to be treated with MitraClip. Based on this approval, Abbott said it will now begin discussions with the Center for Medicare and Medicaid Services (CMS) and physician specialty societies to request a revision to the national coverage determination that would expand Medicare coverage to include secondary MR patients.The indication was supported by the results of the COAPT T...
Source: MDDI - March 15, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

MitraClip Valve Repair Device Gets Expanded Indication MitraClip Valve Repair Device Gets Expanded Indication
The FDA has approved the MitraClip for use in patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - March 14, 2019 Category: Universities & Medical Training Tags: Cardiology News Source Type: news

Abbott Receives FDA Approval for Expanded Indication for MitraClip ™ Device
- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation (Source: Abbott.com)
Source: Abbott.com - March 14, 2019 Category: Pharmaceuticals Source Type: news

Abbott wins expanded indications for MitraClip
The FDA today said that it granted Abbott (NYSE:ABT) a new indication for its MitraClip system, expanding coverage of the device to patients with normal mitral valves with diminished left heart function. The indication expands upon the original approval, which the Chicago-area medical device maker won in 2013, clearing it for use in reducing mitral regurgitation in patients with mitral valve abnormalities whose risks for mitral valve surgery were prohibitive. With its new clearance, the MitraClip is cleared for use for patients with normal mitral valves who develop heart failure symptoms and moderate-to-severe or...
Source: Mass Device - March 14, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Featured Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news

FDA Approves New Indication for Valve Repair Device to Treat Certain Heart Failure Patients with Mitral Regurgitation
SILVER SPRING, Md., March 14, 2019 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today approved a new indication for a heart valve repair device that is intended to reduce moderate-to-severe or severe mitral regurgitat... Devices, Interventional, Cardiology, FDA Abbott Vascular, MitraClip, mitral valve, mitral regurgitation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2019 Category: Pharmaceuticals Source Type: news

FDA approves new indication for valve repair device to treat certain heart failure patients with mitral regurgitation
Device is for treatment of patients to reduce mitral regurgitation in certain patients with heart failure symptoms who fail to respond to traditional therapy (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 14, 2019 Category: American Health Source Type: news

CRF research to be presented at ACC.19
(Cardiovascular Research Foundation) Research from the Cardiovascular Research Foundation and the CRF Clinical Trials Center will be presented at the American College of Cardiology's 68th Annual Scientific Session taking place March 16-18, 2019 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. They will be presenting the latest data on percutaneous coronary intervention (PCI), imaging technologies, renal denervation, and transcatheter aortic valve replacement. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 14, 2019 Category: International Medicine & Public Health Source Type: news

Admedus wins CE Mark for CardioCel 3D, VascuCel products
Admedus (ASX:AHZ)  has won CE Mark approval in the European Union for its CardioCel 3D and VascuCel products which use its proprietary Adapt tissue technology, according to a report from ProactiveInvestors. The Australian company plans to begin the first stage of a commercial launch of the devices in the region later this month, according to the report. “After our initial positive experience with Adapt we are excited to have the choice of these 3D shaped products that will produce better reconstructions for complex aortic arch repair surgeries,” Dr. Tomasz Mroczek said, according to ProactiveInvestors...
Source: Mass Device - March 12, 2019 Category: Medical Devices Authors: Fink Densford Tags: Regenerative Medicine Regulatory/Compliance Admedus Ltd. Source Type: news

Neovasc advances warrant exchange from CardiAQ case
Neovasc (NSDQ:NVCN) said today that it inked an exchange deal for the last of the warrants it issued as part of a $65 million funding round to cover the damages from litigation with Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve. The Vancouver-based replacement heart valve developer said it plans to exchange the Series A and Series E warrants it issued in November 2017 to cover the $42 million balance from its loss in the CardiAQ lawsuit. The deals call for Neovasc to issue more than 496,000 shares in exchange for nearly 58.4 million warrants, which works out to 0.0085 shares per warrant. “We ...
Source: Mass Device - March 12, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Legal News Replacement Heart Valves Wall Street Beat neovasc Source Type: news

Edwards Makes Significant Moves in the Mitral Valve Space
Edwards Lifesciences bolstered its presence in the mitral valve space through a pair of transactions it announced Monday. The Irvine, CA based company invested $35 million in an exclusive right to acquire Corvia Medical and in addition the firm obtained certain assets of Mitralign for an undisclosed sum. Edwards investments come on the heels of Boston Scientific exercising its option to acquire the remaining shares of Millipede Inc. for $325 million. In addition, the Marlborough, MA-based company said a $125 million payment becoming available upon achievement of a commercial milestone. Tewksbury, MA-based Corvia Medical&ac...
Source: MDDI - March 11, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Edwards Lifesciences gets in on Corvia, Mitralign
Edwards Lifesciences (NYSE:EW) said today that it made a pair of strategic bets on the structural heart space, paying $35 million for the right to acquire Corvia Medical and paying an unspecified amount for some of mitral valve repair device maker Mitralign‘s assets. Tewksbury, Mass.-based Corvia is developing an interatrial shunt to treat heart failure by creating a small opening between the left and right atria to lower blood pressure in the left atrium and lungs. The device has CE Mark approval in the European Union and a pivotal U.S trial aimed at winning a nod from the FDA is under way, Edwards said. &ldquo...
Source: Mass Device - March 11, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Implants Featured Mergers & Acquisitions Replacement Heart Valves Edwards Lifesciences Source Type: news

Ohio State ’s 3-D modeling technology for heart patients assists surgeons
The Ohio State University Wexner Medical Center is using 3-D printing technology to help surgeons determine the best methods of replacing aortic valves in their patients ’ hearts. Ohio State Wexner Medical Center physicians and biomedical engineers from Ohio State’s College of Engineering have partnered to develop 3-D printed models of the aortic valves and their neighboring heart structures so that the doctors can predict potential complications in valve repla cement surgery. Aortic valves most… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 7, 2019 Category: American Health Authors: The Ohio State University Wexner Medical Center Source Type: news

2011 to 2015 Saw Drop in Delayed Discharge Rates After TAVR
TUESDAY, March 5, 2019 -- From 2011 to 2015, there was a decline in the rates of delayed discharge following transcatheter aortic valve replacement, according to research published in the March 11 issue of JACC: Cardiovascular... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 5, 2019 Category: Pharmaceuticals Source Type: news

Study of Boston Scientific ’s Lotus, Medtronic’s CoreValve shows similar outcomes at 2 years
Two-year results from a head-to-head study comparing transcatheter aortic heart valve replacement devices from both Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) indicated similar outcomes for the competing products. The study, published recently in the journal JAMA Cardiology, compared Marlborough, Mass.-based Boston Scientific’s Lotus valve to Fridley, Minn.-based Medtronic’s CoreValve system. Investigators in the study compared outcomes for 912 patients with high or extreme risk and severe, symptomatic aortic stenosis after treatment with one of the two devices. Patients, treated between Se...
Source: Mass Device - February 28, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Featured Replacement Heart Valves Boston Scientific Medtronic Source Type: news

Mitral valve repair and mitral valve replacement
are procedures that may be performed to treat diseases of the mitral valve -- the valve located between the left heart chambers (left atrium and left ventricle). Several types of mitral valve disease exist. In mitral valve regurgitation, the flaps (leaflets) of the mitral valve don't close tightly, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 28, 2019 Category: Databases & Libraries Source Type: news

Swiss heart valve dev Novostia raises $7m
Swiss cardiovascular device developer Novostia said today it raised $6.5 million (CHF 6.5 million) to support its novel heart valve device. The Neuchâtel-based company said that the valve, which will be designed for use as both an aortic and mitral valve replacement, is designed from the company’s proprietary high-performance biocompatible polymer. Novostia said that the design, as well as the materials that make up the valve, eliminate the need for lifelong anticoagulant medication use or future replacements as well as the elimination of clicking noises often associated with the valves. “Our technology s...
Source: Mass Device - February 22, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular Featured Replacement Heart Valves Wall Street Beat novostia Source Type: news